Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: FEC100|DRUG: Docetaxel|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Carboplatin
Sponsor: UNICANCER